# Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

> **NCT00323050** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 468 (actual)

## Conditions studied

- Neisseria Meningitidis
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** Haemophilus influenzae type b- and meningococcal (vaccine)

## Key facts

- **NCT ID:** NCT00323050
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323050, "Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00323050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*